The UK and US have forged a landmark trade agreement that will preserve zero import taxes on UK drug exports going into the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to increase expenditure on medicines through the NHS. This move guarantees that import taxes on these crucial products will be held at zero for a period of three years.
This deal is in response to recent threats to significantly raise duties on patented drug products, with potential rates floated as high as 100%.
"This agreement between the UK strengthens the worldwide climate for new treatments and introduces much-needed fairness to American-British medicine commerce," an announcement noted.
Trade Impact
Pharmaceuticals constitute one of the UK's biggest export categories to the United States, which is clearly the primary buyer for large UK drugmakers.
Trade data show that in the 12 months to the end of last September, the UK sold drugs totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of all goods exports in that span.
"This agreement secures employment, increases capital expenditure and sets the stage for the UK to emerge as a international leader for medical research," a minister stated.
Detailed NHS Changes
The pact includes several specific pledges from the UK:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. Previously, rebates were more than twenty percent.
Broader Context
The pact follows a protracted dispute between the sector and the ministers over drug pricing and NHS adoption.
This friction were intensified by assertions that US customers were charged significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or scrapped, while substantial funding commitments have been pledged toward American operations.
One official stated that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a percentage of its overall budget over the past decade.
